Journal article
EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants
Authors
Carbonell-Estrany X; Fullarton J; Keary I; Rodgers-Gray B; Tarride J; Paes B
Journal
Value in Health, Vol. 25, No. 12, pp. s137–s138
Publisher
Elsevier
Publication Date
December 2022
DOI
10.1016/j.jval.2022.09.663
ISSN
1098-3015